Obermatt
See Similar Stocks →

Enanta Pharmaceuticals

NSQ:ENTA · US29251M1062
BiotechnologySmall

360

62
Profit price77
Owner Earnings Yield1
Dividend Yield1
Price/Sales36
EV / Gross Profit50
Price/Book33
Return on Capital73
Cash Return on Capital42
Return on Equity46
EBIT Margin34
Gross Profitability79
Accruals39
Owner Earnings Margin56
Sales growth46
Profit growth29
Reinvestment1
Price momentum61
Debt load24
Refinancing56
Debt Payback1
Liquidity21
Analyst ratings79
Opinion Changes14
Price Target Upside22
Market mood4
Value Creation8/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Enanta Pharmaceuticals clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded1995
Employees122
Websiteenanta.com
ISINUS29251M1062
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
DermatologyRespiratoryImmunologyInflammationInfectious DiseasesHepatologyBiotechnologyHealth CarePharmaceutical

Description

Enanta Pharmaceuticals, Inc. operates as a biotechnology company. The company discovers and develops small molecule drugs with an emphasis on virology and immunology. The company discovered glecaprevir, the second of two antiviral protease inhibitor…

Analysis

Middle-of-the-road

Enanta Pharmaceuticals, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is adequate. The company scores 8/20 on our value-creation score: creating some value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
1
2026

All-time high

12

Mar 2026

All-time low

1

Jun 2026

Average rank

7

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
36
—
—
—
Price/Earnings
69
—
—
—
Price/Book
33
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
39
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Enanta Pharmaceuticals with its peers
Mirum Pharmaceuticals
NMQ:MIRM
40
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Moderna
NSQ:MRNA
20
CountryUSA
IndustryBiotechnology
SizeX-Large
Full Stock Analysis →
Krystal Biotech
NSQ:KRYS
96
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Puma Biotechnology
NSQ:PBYI
79
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Contineum Therapeutics
NSQ:CTNM
80
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Opus Genetics
NAQ:IRD
52
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →